References
- 1. Venkataraman L, Burakoff SJ, Sen R. FK-506 inhibits antigen receptor-mediated induction of C-rel in B and T lymphoid cells. J Exp Med. 1995;181:1091-1099.10.1084/jem.181.3.109121919247532676
- 2. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000;59:323-389.10.2165/00003495-200059020-0002110730553
- 3. Kang JS, Lee MH. Overview of therapeutic drug monitoring. The Korean Journal of Internal Medicine. 2009;24:1-10.10.3904/kjim.2009.24.1.1268765419270474
- 4. Wong G, Howard K, Chapman JR, Chadban S et al. Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS ONE 2012;7:1-9.10.1371/journal.pone.0029591326116022279541
- 5. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374-384.10.2215/CJN.0379110617699437
- 6. Wallemacq P, Armstrong VW, Brunet M et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the european consensus conference. Ther Drug Monit. 2009;31:139-152.10.1097/FTD.0b013e318198d09219177031
- 7. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006, 354:2473-2483.10.1056/NEJMra05441516760447
- 8. Koo DDH, Welsh KI, McLaren AJ et al. Cadaver versus living donor kidneys: Impact of donor factors on antigen induction before transplant. Kidney International 1999;56:1551-1559.10.1046/j.1523-1755.1999.00657.x10504507
- 9. Gjertson DW, Cecka JM. Living unrelated donor kidney transplantation. Kidney International 2000;58:491-499.10.1046/j.1523-1755.2000.00195.x10916072
- 10. Kanellis J. Justification for living donor kidney transplantation. Nephrology 2010;15:S72-S79.10.1111/j.1440-1797.2009.01212.x20591049
- 11. Zivcic-Cosic S, Trobonjaca Z, Racki S. Immunosuppressive treatment for kidney transplantation. Prilozi 2011;32:87-103.
- 12. Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009;4:481–508.10.2215/CJN.04800908
- 13. Michael F. Crutchlow, Roy D. Bloom. Transplant-associated hyperglycemia: A new look at an old problem.Clin J Am Soc Nephrol 2007;2:343–355.10.2215/CJN.03671106
- 14. Pirsch J, Bekersky I, Vincenti F et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 2000;40:527-532.10.1177/00912700022009143
- 15. Hasselink DA, Ngyuen H, Wabbijin M et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when use in combination with corticosteroids. Br J Clin Pharmacol 2003;56:327-330.10.1046/j.0306-5251.2003.01882.x
- 16. Butani L, Berg G, Makker SP. Effect of felodipine on tacrolimus in a renal transplant recipient. Transplantation 2002;73:159.10.1097/00007890-200201150-00033
- 17. Boubenider S, Vincent I, Lambotte O et al. Interaction between theophylline and tacrolimus in a renal transplant pacient. Nephrol Dial Transplant 2000;15:1066-1068.10.1093/ndt/15.7.1066
- 18. Floren LC, Bekersky I, Benet LZ et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Farmacol Ther 1997;62:41-49.10.1016/S0009-9236(97)90150-8
- 19. Michelangelo V, Piero D, Elisa C et al. Grapefruit juice and kinetics of tacrolimus. J Am Soc Nephrol 2001;12:862.
- 20. Egashira K, Fukuda E, Onga T et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant pacient. Transplantation 2003;75:1057.10.1097/01.TP.0000058545.35041.BE12698101
- 21. Kurzawski M, Dąbrowska J, Dziewanowski K et al. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics 2014;15:179-188.10.2217/pgs.13.19924444408